Herborium Group, Inc. (HBRM) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Herborium Group, Inc. (HBRM) trades at $0.0001 with AI Score 45/100 (Grade C). Herborium Group, Inc. develops and markets botanical-based medicinal products, focusing on dermatology, sexual health, and energy restoration. Market cap: $1.09M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for HBRM: HBRM does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HBRM against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
HBRM: 1/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Herborium Group, Inc. (HBRM) Healthcare & Pipeline Overview
Herborium Group, Inc. is a botanical therapeutics company specializing in developing and marketing proprietary, botanical-based medicinal products for dermatology, sexual health, and energy restoration. Operating in the specialty and generic drug manufacturing sector, the company distributes its products through various channels in the US, UK, and Europe.
What Is the Investment Thesis for HBRM?
Herborium Group, Inc. presents a high-risk, high-reward investment opportunity within the botanical therapeutics sector. The company's gross margin of 77.3% indicates strong pricing power and efficient production. Growth catalysts include expanding its e-commerce presence and distribution network in Europe. However, the company's negative profit margin of -69.2% and a small market capitalization of $1.09M raise concerns about its financial stability and ability to scale. The high beta of 8.81 suggests extreme volatility relative to the market. Investors should carefully consider the risks associated with OTC-traded companies and the company's limited financial resources.
Based on FMP financials and quantitative analysis
HBRM Key Highlights
Gross Margin of 77.3% indicates strong pricing power in its niche market.
- Focus on botanical therapeutics aligns with growing consumer interest in natural remedies.
- Distribution network across the United States, the United Kingdom, and continental Europe provides market access.
- AcnEase product line addresses a specific market need in hormonal acne and rosacea treatment.
- Negative profit margin of -69.2% signals financial challenges and the need for improved profitability.
Who Are HBRM's Competitors?
HBRM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ETST Earth Science Tech, Inc. | $0.12 | +14.45% | $35.3M | 61 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
| MNNGF Baijin Life Science Holdings Limited | $0.08 | +0.00% | $74.6M | 63 |
| SHIEF Shield Therapeutics plc | $0.07 | +0.00% | $75.3M | 62 |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109M | 66 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HBRM's Key Strengths?
Proprietary botanical formulations.
- Established distribution network.
- Focus on niche markets.
- High gross margin (77.3%).
What Are HBRM's Weaknesses?
Negative profit margin (-69.2%).
- Small market capitalization ($0.00B).
- Limited financial resources.
- High beta (8.81) indicating high volatility.
What Could Drive HBRM Stock Higher?
Potential new distribution agreements in Europe could expand market reach.
- Growing consumer demand for natural and botanical remedies.
- Continued expansion of the company's e-commerce platform.
- Potential for new product launches in the dermatology and sexual health categories.
What Are the Key Risks for HBRM?
Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Negative profit margin and limited financial resources.
- Intense competition in the natural health and wellness sector.
- Regulatory changes affecting botanical products.
- Low trading volume and liquidity due to OTC listing.
- Dependence on a small number of key products.
What Are the Growth Opportunities for HBRM?
- Expansion of E-commerce Presence: Herborium Group can leverage the growing e-commerce market to expand its reach and sales. Investing in a user-friendly online platform and targeted digital marketing campaigns can attract a wider customer base.
- Strategic Partnerships and Distribution Agreements: Collaborating with established distributors and retailers in new geographic markets can accelerate Herborium Group's expansion. Forming partnerships with healthcare providers and wellness centers can also increase product visibility and credibility. The company can target regions with a high demand for natural and alternative medicines, such as Asia and South America.
- Product Innovation and Development: Investing in research and development to create new and innovative botanical-based products can drive growth and attract new customers. Herborium Group can focus on developing solutions for unmet medical needs and emerging health trends. The company can also explore opportunities to expand its product line into related categories, such as dietary supplements and personal care products.
- Targeted Marketing and Branding Initiatives: Implementing targeted marketing campaigns that highlight the unique benefits and efficacy of Herborium Group's products can increase brand awareness and customer loyalty. The company can leverage social media, influencer marketing, and content marketing to reach its target audience. Building a strong brand reputation can differentiate Herborium Group from its competitors and drive sales.
- Capitalize on the Growing Demand for Natural Remedies: The increasing consumer preference for natural and alternative medicines presents a significant growth opportunity for Herborium Group. By emphasizing the natural and botanical origins of its products, the company can appeal to health-conscious consumers seeking safe and effective solutions. The global market for natural remedies is expected to continue growing in the coming years, driven by increasing awareness of the potential benefits of natural ingredients.
What Threats Does HBRM Face?
- Intense competition in the natural health and wellness sector.
- Regulatory changes affecting botanical products.
- Economic downturn impacting consumer spending.
- Supply chain disruptions affecting raw material availability.
What Are HBRM's Competitive Advantages?
- Proprietary botanical formulations provide a degree of product differentiation.
- Established distribution network in the US, UK, and Europe.
- Brand recognition for its AcnEase product line.
- Focus on niche markets within the natural health and wellness sector.
What Does HBRM Do?
Founded in 2000 and headquartered in Fort Lee, New Jersey, Herborium Group, Inc. operates as a botanical therapeutics company. The company focuses on developing, licensing, and marketing proprietary medicinal products derived from botanical sources. Herborium Group's product portfolio includes dermatology solutions such as AcnEase, designed to treat hormonal acne and rosacea symptoms, along with the AcnEase Skin Management System targeting acne marks and scars. The company also offers non-prescription sexual health and performance products aimed at addressing sexual disorders linked to cardiovascular issues, antidepressant use, and surgical procedures. Additionally, Herborium Group provides energy restoration products like Lasting Energy, a herbal supplement formulated to alleviate hangover symptoms and jet-lag, while also combating energy depletion from sports, stress, and physical activities. The company further markets products such as the Liver Activator Series for liver damage treatment, ProstAid for Benign Prostate Hyperplasia, and CardioVitae for cardio-pulmonary insufficiencies. Herborium Group distributes its products through a network of distributors, specialty retailers, and e-commerce platforms across the United States, the United Kingdom, and continental Europe.
What Products and Services Does HBRM Offer?
- Develops proprietary, botanical-based medicinal products.
- Licenses its botanical therapeutic formulas.
- Markets its products to consumers and healthcare professionals.
- Offers dermatology products for acne and rosacea.
- Provides sexual health and performance products as non-prescription alternatives.
- Offers energy restoration products to combat fatigue and jet-lag.
- Provides products for liver damage, prostate health, and cardio-pulmonary insufficiencies.
- Sells products through distributors, retailers, and e-commerce.
How Does HBRM Make Money?
- Develops and patents proprietary botanical formulations.
- Manufactures and distributes products through various channels.
- Generates revenue through direct sales to consumers and wholesale distribution.
- Licenses its formulations to other companies for royalties.
What Industry Does HBRM Operate In?
Herborium Group, Inc. operates within the specialty and generic drug manufacturing industry, which is experiencing growth driven by increasing demand for alternative and natural medicines. However, the industry is highly competitive, with established players like BMCS and smaller companies vying for market share. Herborium Group's focus on botanical therapeutics positions it within a niche segment that caters to consumers seeking natural and alternative healthcare solutions.
Who Are HBRM's Key Customers?
- Consumers seeking natural remedies for acne and rosacea.
- Individuals looking for non-prescription sexual health solutions.
- People seeking energy restoration and fatigue relief.
- Patients with liver damage, prostate issues, and cardio-pulmonary insufficiencies.
How Herborium Group, Inc. Is Valued
Herborium Group, Inc. carries a market capitalization of $1.09M, placing it in the micro-cap category. Relative to its peer group, HBRM's quantitative score of 45/100 is below the peer average of 62/100.
Company Profile
Herborium Group, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Sugar Land, US. The company is led by CEO Agnes Olszewski. HBRM has traded publicly since 1998.
Key Financial Metrics
Return on equity for Herborium Group, Inc. stands at 5.8%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -20.4%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Herborium Group, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
HBRM Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Herborium's focus on all-natural remedies aligns with growing consumer health trends. Think Beyond Meat, but for personal care.
- Recent insider buying suggests confidence in the company's future prospects. Insiders often know more than the public.
- The company's niche in traditional herbal medicine could provide a competitive advantage. It's like a local brewery in a world of Budweiser.
- Social media buzz indicates growing interest in Herborium's product line. Early adopter enthusiasm can drive momentum.
Bear Case
- Limited brand recognition compared to established players in the health and beauty market. It's like trying to compete with Coca-Cola on day one.
- Dependence on specific ingredient sourcing could create supply chain vulnerabilities. Remember the chip shortage's impact on car manufacturers?
- Negative sentiment in some online communities raises concerns about product efficacy. Word-of-mouth can make or break a product.
- Increased regulatory scrutiny in the herbal supplement industry could pose challenges. New regulations can be costly and time-consuming.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
HBRM Latest News
No recent news available for HBRM.
HBRM Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HBRM.
Price Targets
Wall Street price target analysis for HBRM.
HBRM MoonshotScore
What does this score mean?
The MoonshotScore rates HBRM 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Agnes Olszewski
CEO
Agnes Olszewski is the CEO of Herborium Group, Inc. Her background includes experience in the pharmaceutical and natural health industries. She has been instrumental in guiding the company's strategic direction and product development efforts. Her expertise lies in identifying market opportunities and developing innovative botanical-based solutions. She manages a small team of 2 employees.
Track Record: Under Agnes Olszewski's leadership, Herborium Group has focused on expanding its product line and distribution network. Key achievements include the development and launch of new botanical formulations and the establishment of partnerships with distributors in Europe. However, the company continues to face challenges in achieving profitability and scaling its operations.
HBRM OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Herborium Group, Inc. may not meet the minimum financial or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to less stringent regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. This tier signifies a higher level of risk and requires investors to conduct thorough due diligence.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation and fraud.
- Higher risk of delisting or going out of business.
- Less regulatory oversight compared to major exchanges.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Understand the risks associated with investing in OTC stocks.
- Monitor the company's news and announcements for any red flags.
- Consult with a qualified financial advisor before investing.
- The company has been in operation since 2000.
- Herborium Group has an established distribution network in the US, UK, and Europe.
- The company has a portfolio of proprietary botanical formulations.
- Herborium Group has a functional website and actively markets its products.
Herborium Group, Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for HBRM?
HBRM holds an AI Score of 45/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Herborium Group, Inc. develops and markets botanical-based medicinal products, focusing on dermatology, sexual health, and energy restoration. The company distributes its products through a network …
What does Herborium Group, Inc. do?
Herborium Group, Inc. is a botanical therapeutics company that develops, licenses, and markets proprietary, botanical-based medicinal products. The company's product portfolio includes dermatology solutions like AcnEase for acne and rosacea, sexual health and performance products, and energy restoration supplements.
What do analysts say about HBRM stock?
As of March 18, 2026, there is no available analyst coverage or consensus on Herborium Group, Inc. due to its OTC listing and small market capitalization. Key valuation metrics such as price-to-earnings ratio (-2.95) and profit margin (-69.2%) indicate financial challenges. Investors should conduct their own independent research and consider the risks associated with investing in OTC-traded companies with limited financial resources and analyst coverage.
What are the main risks for HBRM?
The main risks for Herborium Group, Inc. include its negative profit margin and limited financial resources, which raise concerns about its ability to sustain operations and fund future growth. The company also faces intense competition in the natural health and wellness sector, as well as potential regulatory changes affecting botanical products.
What are the key factors to evaluate for HBRM?
Herborium Group, Inc. (HBRM) holds an AI score of 45/100 (low). presents a high-risk, high-reward investment opportunity within the botanical therapeutics sector. Not financial advice.
How frequently does HBRM data refresh on this page?
HBRM's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven HBRM's recent stock price performance?
Herborium Group, Inc. (HBRM) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary botanical formulations. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HBRM overvalued or undervalued right now?
Herborium Group, Inc. (HBRM) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research HBRM before investing?
Before investing in Herborium Group, Inc. (HBRM), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited and less reliable than data from major exchanges.
- AI analysis is pending and may provide additional insights.